Non-Invasive Biomarkers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma-A Systematic Review.

biomarkers upper urinary tract urothelial carcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Mar 2022
Historique:
received: 10 02 2022
revised: 11 03 2022
accepted: 14 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Beyond laboratory, imaging and endoscopic procedures, new diagnostic tools are increasingly being sought for the diagnosis of upper urinary tract urothelial carcinoma (UTUC), especially those that are non-invasive. In this systematic review, we aimed to determine the effectiveness of non-invasive tests in the diagnosis of UTUC. PubMed and Embase electronic databases were searched to identify studies assessing effectiveness of non-invasive tests in the primary diagnosis of UTUC. The study protocol was registered with PROSPERO (CRD42020216480). Among 10,084 screened publications, 25 were eligible and included in the analysis. Most of them were conducted on small samples of patients and the control groups were heterogenous. The test used in the largest number of studies was voided urinary cytology, which has poor sensitivity (11-71.1%) with favorable specificity (54-100%). Fluorescence in situ hybridization in diagnostic cytology showed higher sensitivity (35-85.7%) with equally good specificity (80-100%). There were also studies on the use of tests known to diagnose bladder cancer such as NMP22, uCYT or BTA test. Other urine or blood tests have been the subject of only isolated studies, with varying results. To conclude, currently there is a lack of high-quality data that could confirm good effectiveness of non-invasive tests used in the diagnosis of UTUC.

Identifiants

pubmed: 35326672
pii: cancers14061520
doi: 10.3390/cancers14061520
pmc: PMC8945959
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Urology. 2001 Oct;58(4):532-5
pubmed: 11597532
J Cancer Res Ther. 2017;13(4):647-650
pubmed: 28901308
Oncol Lett. 2017 May;13(5):3928-3934
pubmed: 28529600
Eur Urol Oncol. 2020 Feb;3(1):73-79
pubmed: 31591037
Diagn Cytopathol. 2017 Oct;45(10):895-902
pubmed: 28799728
Cancer Genet Cytogenet. 2010 Dec;203(2):238-46
pubmed: 21156239
Urology. 2007 Oct;70(4):753-7
pubmed: 17991550
Eur Urol Focus. 2021 Mar 15;:
pubmed: 33737024
World J Urol. 2020 May;38(5):1165-1175
pubmed: 31321509
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Acta Cytol. 2012;56(5):533-8
pubmed: 23075895
Transl Androl Urol. 2018 May;7(Suppl 2):S248-S251
pubmed: 29928626
Oncol Lett. 2016 Jul;12(1):183-188
pubmed: 27347122
Transl Androl Urol. 2016 Oct;5(5):636-647
pubmed: 27785420
Cancer Genet Cytogenet. 2009 Mar;189(2):93-7
pubmed: 19215789
Front Psychiatry. 2020 May 15;11:432
pubmed: 32499729
Urology. 2011 Mar;77(3):636-41
pubmed: 21256577
Int J Clin Oncol. 2019 Sep;24(9):1075-1080
pubmed: 30976938
J Endourol. 2008 Jun;22(6):1371-4
pubmed: 18578665
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Acta Chir Iugosl. 2007;54(4):19-24
pubmed: 18595223
Int J Mol Sci. 2017 Dec 06;18(12):
pubmed: 29210993
Clin Cancer Res. 2010 Dec 1;16(23):5842-51
pubmed: 20975101
BJU Int. 2011 Apr;107(7):1059-64
pubmed: 20825397
Urol Oncol. 2011 Nov-Dec;29(6):716-23
pubmed: 20056458
Urology. 2001 Sep;58(3):362-6
pubmed: 11549481
PLoS One. 2015 Jan 28;10(1):e0117284
pubmed: 25629698
J Urol. 2021 Feb;205(2):392-399
pubmed: 32935620
Biomed Pharmacother. 2019 May;113:108744
pubmed: 30844659
Neoplasma. 2012;59(4):355-60
pubmed: 22489689
Am J Surg Pathol. 2018 Nov;42(11):1549-1555
pubmed: 30148743
Cancer Cytopathol. 2021 Dec;129(12):984-995
pubmed: 33979039
Urol Int. 2011;87(2):134-7
pubmed: 21865670
Eur J Cancer. 2014 Jan;50(1):226-33
pubmed: 24100025
Curr Pharm Biotechnol. 2017;18(6):445-455
pubmed: 28571562
Mol Med Rep. 2015 Nov;12(5):6752-60
pubmed: 26323574
Oncologist. 2021 Aug;26(8):e1395-e1405
pubmed: 34050578
J Urol. 2010 Apr;183(4):1330-65
pubmed: 20171676
Rom J Morphol Embryol. 1995 Jul-Dec;41(3-4):101-5
pubmed: 8772363
Eur Urol. 2007 Feb;51(2):409-15; discussion 415
pubmed: 17010508
Cancer Sci. 2019 May;110(5):1771-1779
pubmed: 30887605
Can J Urol. 2017 Feb;24(1):8620-8626
pubmed: 28263126
Urol Oncol. 2013 Oct;31(7):1148-54
pubmed: 22130125
J Am Soc Cytopathol. 2019 Jan - Feb;8(1):18-26
pubmed: 30929755

Auteurs

Łukasz Białek (Ł)

Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Konrad Bilski (K)

Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Jakub Dobruch (J)

Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Wojciech Krajewski (W)

Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wrocław, Poland.

Tomasz Szydełko (T)

Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wrocław, Poland.

Piotr Kryst (P)

Second Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Sławomir Poletajew (S)

Second Department of Urology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Classifications MeSH